Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Follow us on Twitter

  • National Cancer Institute is funding research on using programmable synthetic messenger RNA to treat two types of s… https://t.co/kYyOAY6MOf
    about 10 hours ago
  • New post on Science and Enterprise: NIH Funds Programmable mRNA to Treat Cancer https://t.co/DKptaY956d #Science #Business
    about 10 hours ago
  • Attn @ArcticFisheries .. Why Migraine Sufferers May Want to Eat More Fish https://t.co/3AaUvjuNqT
    about 14 hours ago
  • Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and ther… https://t.co/iJUJA00PmY
    about 1 day ago
  • New post on Science and Enterprise: Sanofi Acquires mRNA Developer in $3.2B Deal https://t.co/lRVt9pv3bq #Science #Business
    about 1 day ago

Please share Science & Enterprise

NIH Funds Programmable mRNA to Treat Cancer

Breast cancer self exam

National Cancer Institute is funding research on using programmable synthetic messenger RNA to treat two types of solid tumor cancer. . . . → Read More: NIH Funds Programmable mRNA to Treat Cancer

Sanofi Acquires mRNA Developer in $3.2B Deal

Wall Street sign

Drug maker Sanofi is purchasing biotechnology company Translate Bio, a developer of messenger RNA vaccines and therapies, and a long-time collaborator. . . . → Read More: Sanofi Acquires mRNA Developer in $3.2B Deal

Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

Brain activity graphic

A French biopharmaceutical company is gaining access to a technology using synthetic nucleic acids to treat rare genetic neurological diseases. . . . → Read More: Pharma Gains Synthetic DNA for Rare Diseases in $1B+ Deal

Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

Mitochondria illustration

A biotechnology enterprise is teaming with a pharmaceutical company to develop off-the-shelf therapies for malfunctioning mitochondria, energy centers of cells. . . . → Read More: Pharma, Biotech Partner on Off-the-Shelf Cell Therapies

Fine-Tuning Process Devised for Gene Therapies

Gene therapy graphic

Researchers designed a technique to adjust the volume of proteins from gene therapy released into patients, providing more control for complex diseases. . . . → Read More: Fine-Tuning Process Devised for Gene Therapies

FDA Clears Stem Cell Trial for Multiple Sclerosis

neurons

The Food and Drug Administration has authorized a clinical trial of stem cells extracted and cultured from patients to treat their cases of multiple sclerosis. . . . → Read More: FDA Clears Stem Cell Trial for Multiple Sclerosis

Alzheimer’s Digital Biomarkers Project Gains New Funds

Brain circuits illustration

A venture philanthropy group is funding an initiative to find digital data indicators of early onset of Alzheimer’s disease and other forms of dementia. . . . → Read More: Alzheimer’s Digital Biomarkers Project Gains New Funds

Biotech Opens Gene Therapy Manufacturing Facility

Adeno-associated virus

A biotechnology company serving gene therapy developers is opening a manufacturing facility for engineered viruses that deliver gene therapies. . . . → Read More: Biotech Opens Gene Therapy Manufacturing Facility

Covid-19 Delta Variant Testing Reference Released

Covid-19 testing

A company designing synthetic DNA and RNA says reference materials are available for tests that detect the quickly spreading Covid-19 delta variant. . . . → Read More: Covid-19 Delta Variant Testing Reference Released

Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds

Red blood cells illustration

A start-up company creating synthetic blood vessels for transplants, based on research in materials science and cell biology, is raising $2.2 million in seed funds. . . . → Read More: Synthetic Blood Vessel Maker Gains $2.2M in Seed Funds